# Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2)

> **NCT07713745** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Beijing Tiantan Hospital** · enrollment: 200 (estimated)

## Conditions studied

- Neurofibromatosis Type 2
- Vestibular Schwannoma
- Non-vestibular Schwannoma
- Meningioma
- Ependymoma
- NF2-related Schwannomatosis
- NF2

## Interventions

- **DRUG:** Selumetinib 25mg/m2
- **DRUG:** Luvometinib
- **DRUG:** Serplulimab

## Key facts

- **NCT ID:** NCT07713745
- **Lead sponsor:** Beijing Tiantan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-18
- **Primary completion:** 2036-06-01
- **Final completion:** 2036-12-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07713745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07713745, "Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07713745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*